Anthera Announces Completion Of Enrollment And Dosing In Phase II Trial Of A-002 For The Treatment Of Cardiovascular Disease

Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced the completion of enrollment and patient dosing in its Phase II clinical study of its lead compound, A-002 for stable coronary artery disease. Data analysis is scheduled to be completed by the end of the year. [click link for full article]

More: continued here

Filed under: Cardiovascular on October 5th, 2007